In contrast to previous reports that emphasized the rarity of genetic mutations in epigenetic modifier genes in JMML [8, 19, 22], we identified components of PRC2, including EZH2 and ASXL1, were mutated at diagnosis (9/93, 9.68%). This evidence concerns the gene ASXL1 and juvenile myelomonocytic leukemia.